AIMO, ALBERTO
 Distribuzione geografica
Continente #
NA - Nord America 24.308
AS - Asia 12.833
EU - Europa 12.597
SA - Sud America 3.852
AF - Africa 325
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 21
Totale 53.969
Nazione #
US - Stati Uniti d'America 23.284
SG - Singapore 5.493
RU - Federazione Russa 4.928
BR - Brasile 3.152
CN - Cina 3.038
IT - Italia 2.490
VN - Vietnam 1.722
GB - Regno Unito 1.616
DE - Germania 983
HK - Hong Kong 885
CA - Canada 716
UA - Ucraina 435
IE - Irlanda 429
SE - Svezia 297
AR - Argentina 273
IN - India 273
FI - Finlandia 271
FR - Francia 225
MX - Messico 222
TR - Turchia 216
PL - Polonia 208
BD - Bangladesh 198
ID - Indonesia 183
NL - Olanda 178
IL - Israele 165
ZA - Sudafrica 151
ES - Italia 147
EC - Ecuador 139
JP - Giappone 134
IQ - Iraq 104
PK - Pakistan 101
AT - Austria 95
CO - Colombia 69
DK - Danimarca 69
AE - Emirati Arabi Uniti 58
LT - Lituania 55
UZ - Uzbekistan 52
MA - Marocco 51
PY - Paraguay 51
VE - Venezuela 49
CL - Cile 33
PE - Perù 33
KE - Kenya 30
UY - Uruguay 29
BE - Belgio 28
CH - Svizzera 26
EG - Egitto 26
SA - Arabia Saudita 23
TN - Tunisia 22
AZ - Azerbaigian 19
RO - Romania 18
EU - Europa 17
IR - Iran 17
JO - Giordania 17
BO - Bolivia 16
CZ - Repubblica Ceca 16
DO - Repubblica Dominicana 16
AU - Australia 15
DZ - Algeria 14
KZ - Kazakistan 14
NZ - Nuova Zelanda 11
CR - Costa Rica 10
LB - Libano 10
NP - Nepal 10
AL - Albania 9
HN - Honduras 9
MY - Malesia 9
NI - Nicaragua 9
PA - Panama 9
AM - Armenia 8
GE - Georgia 8
KR - Corea 8
MC - Monaco 8
OM - Oman 8
TW - Taiwan 8
GT - Guatemala 7
GY - Guiana 7
KG - Kirghizistan 7
SK - Slovacchia (Repubblica Slovacca) 7
TH - Thailandia 7
BB - Barbados 6
BY - Bielorussia 6
CI - Costa d'Avorio 6
HU - Ungheria 6
JM - Giamaica 6
PH - Filippine 6
TT - Trinidad e Tobago 6
PS - Palestinian Territory 5
PT - Portogallo 5
BA - Bosnia-Erzegovina 4
BH - Bahrain 4
KW - Kuwait 4
MD - Moldavia 4
ML - Mali 4
SI - Slovenia 4
AO - Angola 3
BG - Bulgaria 3
BN - Brunei Darussalam 3
ET - Etiopia 3
GR - Grecia 3
Totale 53.894
Città #
Dallas 6.173
Singapore 2.940
Ashburn 1.511
Chicago 1.423
Beijing 1.387
Los Angeles 1.178
Moscow 914
Hong Kong 826
Salt Lake City 606
Chandler 562
Ho Chi Minh City 555
Southend 543
Fairfield 462
San Mateo 451
Buffalo 426
Dublin 423
Houston 386
New York 360
Woodbridge 359
Wilmington 355
Hefei 350
Tampa 345
The Dalles 343
São Paulo 324
Cambridge 320
Seattle 304
Hanoi 298
Elk Grove Village 269
Milan 255
Boardman 250
Portsmouth 242
Falls Church 237
Munich 234
Stevenage 215
Santa Clara 213
Ann Arbor 212
Rome 207
Ottawa 203
Pisa 200
Beauharnois 193
Warsaw 186
Jacksonville 179
Brooklyn 159
Dearborn 156
Lawrence 155
Montreal 148
Tel Aviv 147
Florence 146
London 138
Sterling 133
Istanbul 128
Lancaster 126
Tokyo 119
Dong Ket 117
Poplar 117
Stockholm 117
Denver 111
Frankfurt am Main 108
Rio de Janeiro 106
Orem 103
Johannesburg 102
Chennai 99
Phoenix 98
Nuremberg 97
Mexico City 96
Lappeenranta 95
Miami 93
Atlanta 90
Boston 86
Helsinki 84
Belo Horizonte 79
Dulles 78
Toronto 72
Turku 70
San Diego 64
Amsterdam 62
Haiphong 62
Brasília 58
Manchester 58
Da Nang 57
Ankara 56
Bologna 53
Curitiba 53
Detroit 53
San Francisco 53
Biên Hòa 52
Porto Alegre 52
Guangzhou 51
Kansas City 51
Washington 50
Council Bluffs 48
Mumbai 47
Quito 47
Tashkent 46
Campinas 45
Lucca 45
Querétaro 45
Guayaquil 44
Pittsburgh 43
Naples 42
Totale 32.329
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.794
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.600
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology 1.511
Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology 830
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 662
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 552
[ANMCO/ELAS/SIBioC Consensus document: Recommendations for the use of cardiac biomarkers in heart failure patients] 407
[The use of PROMs (patient-reported outcome measures) and PREMs (patient-reported experience measures) in Cardiology: current state and applications to improve patient care] 334
Building medical knowledge from real world registries: The case of heart failure 314
Autonomic, functional, skeletal muscle, and cardiac abnormalities are associated with increased ergoreflex sensitivity in mitochondrial disease 312
A simple echocardiographic score to rule out cardiac amyloidosis 307
Meteorin-like protein is associated with a higher risk profile and predicts a worse outcome in patients with STEMI 305
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 296
"Targeting and Treating Apneas" in "The Breathless Heart: Apneas in Heart Failure" 295
Treating chemoreflex in heart failure: modulation or demolition? 293
Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences 288
Peripheral reflex feedbacks in chronic heart failure: Is it time for a direct treatment? 286
Influence of central apneas and chemoreflex activation on pulmonary artery pressure in chronic heart failure 281
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 281
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 276
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 269
Position paper ANMCO: Impiego di vericiguat nello scompenso cardiaco: dalle evidenze al posizionamento terapeutico 266
A simple echocardiographic score to rule out cardiac amyloidosis 258
Using co-creation to develop a cardiology online open course: an effective approach for implementing digital learning 254
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis 249
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 247
A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets 242
The Fondazione Toscana Gabriele Monasterio app: a digital health system to improve wellbeing of inpatients with heart or lung disease 240
Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure 239
Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy 237
Sex-related differences in chronic heart failure 235
Cardiac light-chain deposition disease relapsing in the transplanted heart 234
How to take arms against central apneas in heart failure 234
Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy 234
[Treatment of cardiac fibrosis: from neurohormonal antagonists to CAR-T cells] 231
COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead 227
Myocardial damage in a mitochondrial myopathy patient with increased ergoreceptor sensitivity and sympatho-vagal imbalance 226
Unmet needs in end-of-life care for heart failure patients 225
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 224
Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry 222
[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis 221
Screening the health status of people working in a university 219
Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction 219
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC) 219
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 218
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 217
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 215
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 215
Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease 214
Exercise intolerance in heart failure with preserved ejection fraction: A reappraisal of central mechanisms? 213
[Ten perspectives for research and innovation in cardiac amyloidosis] 212
Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies 210
Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis 209
Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure 208
The heart after idarubicin overdose. Cardiac death in a patient with acute promyelocitic leukaemia 208
The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy 208
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 206
Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences 206
Echocardiography-Derived Forward Left Ventricular Output Improves Risk Prediction in Systolic Heart Failure 205
Atrial amyloidosis: mechanisms and clinical manifestations 204
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 204
Biomarkers for the diagnosis and management of heart failure 203
Procalcitonin, white blood cell count and C-reactive protein as predictors of S. aureus infection and mortality in infective endocarditis 202
Cardiac troponins as biomarkers for cardiac disease 197
Morphologies and prognostic significance of left ventricular volume/time curves with cardiac magnetic resonance in patients with non-ischaemic heart failure and left bundle branch block 197
Is fat good for arrhythmias in ischemic heart failure? Another face of the obesity paradox 195
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis 195
Biomarkers for the diagnosis and management of heart failure: New frontiers 194
Cardiovascular disease and COVID-19: les liaisons dangereuses 192
Eligibility for vericiguat in a real‐world, contemporary heart failure population 191
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 189
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 189
ANMCO/ELAS/SIBioC Consensus Document: Biomarkers in heart failure 185
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 185
Amiodarone as a possible therapy for coronavirus infection 184
Cardiovascular magnetic resonance for the diagnosis and management of heart failure with preserved ejection fraction 184
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 183
Role of Imaging in Cardiomyopathies 182
The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease 182
The Importance of Visceral Feedbacks: Focus on Chemoreceptors 180
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 180
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 179
Cardiac magnetic resonance in patients with muscular dystrophies 179
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 177
Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure 176
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 176
Management of complications of cardiac amyloidosis: 10 questions and answers 175
Effects of pirfenidone on scar size and ventricular remodeling after myocardial infarction: a preclinical study 174
Approccio critico all’interpretazione dei trial cardiovascolari con risultati neutri o negativi 174
Subclinical cardiac damage in cancer patients before chemotherapy 174
Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis 174
Big gamma-glutamyltransferase is associated with epicardial fat volume and cardiovascular outcome in the general population 173
Valvular heart disease in patients with cardiac amyloidosis 171
Disease features and management of cardiomyopathies in women 171
Perspectives in noninvasive imaging for chronic coronary syndromes 170
Remote Ischemic Conditioning in Ischemic Stroke and Myocardial Infarction: Similarities and Differences 170
Molecular autopsy of sudden cardiac death in the genomics era 170
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis 169
Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week 169
Factors for heterogeneous outcomes of angina and myocardial ischemia without obstructive coronary atherosclerosis 169
Totale 27.546
Categoria #
all - tutte 296.002
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 296.002


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.541 0 0 0 0 0 321 143 129 217 158 252 321
2021/20222.538 177 295 65 231 108 145 298 491 203 285 52 188
2022/20231.732 162 165 75 154 210 208 42 155 341 43 121 56
2023/20241.762 107 49 336 122 75 154 106 71 88 96 95 463
2024/202519.303 220 243 878 362 665 803 1.951 3.264 1.352 2.531 4.186 2.848
2025/202624.598 2.194 6.182 4.866 5.533 4.011 1.812 0 0 0 0 0 0
Totale 54.366